HORSHAM, Pa. November 5, 2010 – Innovative health care market research firm Verilogue continues its trend of rapid growth with the announcement that it now provides pharmaceutical marketers with the same unique insight into the physician-patient conversation on a global scale. As it moves into the European market, Verilogue remains true to its core business of delivering solutions that focus on naturally-occurring dialogue between physicians and patients. This new global market research offering provides an exciting option for conducting in-depth market research in real physician practices across multiple countries all over the world.
“We are thrilled to grow our unique, innovative approach to health care dialogue research at an international level,” said Verilogue CEO Jeff Kozloff. “Our clients benefit from an improved understanding of variations in the physician-patient dynamic across different countries, and this understanding leads to smarter communication strategies and ultimately better patient care. The convenience of concurrently handling market research initiatives at multiple locations around the globe is sure to be a very efficient solution for our partners in the pharmaceutical arena.”
Verilogue has achieved a number of additional growth milestones in 2010, including:
- Launching a new pharmaceutical sales training division
- Surpassing 60,000 digitally recorded physician-patient conversations covering more than 75 therapeutic categories
- Working with over 100 unique pharmaceutical brand teams
- Completion of an EU pilot study which yielded over 100 conversations from several physician specialties and disease states
Verilogue’s insight into real-time physician-patient conversations can be applied to a number of business challenges, including product positioning, marketing message development, new product launches, and competitive awareness.
